Corrigendum to “Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury” (Bioorganic & Medicinal Chemistry Letters (2019) 29(8) (995–1000), (S0960894X19300873), (10.1016/j.bmcl.2019.02.011))

Maria B. Goncalves, Earl Clarke, Christopher I. Jarvis, S. Barret Kalindjian, Thomas Pitcher, John Grist, Carl Hobbs, Thomas Carlstedt, Julian Jack, Jane T. Brown, Mark Mills, Peter Mumford, Alan D. Borthwick^*, Jonathan P.T. Corcoran

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Corrigendum to “Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury” (Bioorganic & Medicinal Chemistry Letters (2019) 29(8) (995–1000), (S0960894X19300873), (10.1016/j.bmcl.2019.02.011))'. Together they form a unique fingerprint.

Corrigendum to “Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury” (Bioorganic & Medicinal Chemistry Letters (2019) 29(8) (995–1000), (S0960894X19300873), (10.1016/j.bmcl.2019.02.011))

Fingerprint

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Nursing and Health Professions